Navigation Links
Focus on glaucoma origins continues path toward potential cure
Date:1/17/2012

Glaucoma is the second leading cause of blindness. Nearly 4 million Americans have the disorder, which affects 70 million worldwide. There is no cure and no early symptoms. Once vision is lost, it's permanent.

New findings at Georgia Tech, published in January during Glaucoma Awareness Month, explore one of the many molecular origins of glaucoma and advance research dedicated to fighting the disease.

Glaucoma is typically triggered when fluid is unable to circulate freely through the eye's trabecular meshwork (TM) tissue. Intraocular pressure rises and damages the retina and optic nerve, which causes vision loss. In certain cases of glaucoma, this blockage results from a build-up of the protein myocilin. Georgia Tech Chemistry and Biochemistry Assistant Professor Raquel Lieberman focused on examining the structural properties of these myocilin deposits.

"We were surprised to discover that both genetically defected as well as normal, or wild-type (WT), myocilin are readily triggered to produce very stable fibrous residue containing a pathogenic material called amyloid," said Lieberman, whose work was published in the most recent Journal of Molecular Biology.

Amyloid formation, in which a protein is converted from its normal form into fibers, is recognized as a major contributor to numerous non-ocular disorders, including Alzheimer's, certain forms of diabetes and Mad Cow disease (in cattle). Scientists are currently studying ways to destroy amyloid fibrils as an option for treating these diseases. Further research, based on Lieberman's findings, could potentially result in drugs that prevent or stop myocilin amyloid formation or destroy existing fibrils in glaucoma patients.

Until this point, amyloids linked to glaucoma had been restricted to the retinal area. In those cases, amyloids kill retina cells, leading to vision loss, but don't affect intraocular pressure.

"The amyloid-containing myocili
'/>"/>

Contact: Jason Maderer
maderer@gatech.edu
404-385-2966
Georgia Institute of Technology
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Lung cancer conference to focus on new diagnostic techniques, potential treatments
2. Predictive health symposium will focus on human microbiome
3. Conservationists call for increased focus on coastal ecosystems
4. New book from NJIT professor focuses on art, science and evolution
5. Focus on fats
6. First NIH-funded personalized drug development center in US will focus on muscle disease
7. Fate of lakes focus of international meeting in Sunapee, N.H.
8. Journal focuses on Savannah River National Labratory, Chernobyl Laboratory collaboration
9. Researchers develop optimal algorithm for determining focus error in eyes and cameras
10. International pharmacogenomics conference to focus on better drug treatment based on genetics
11. October 2011 conference focuses on the role of gender in cardiovascular disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Focus on glaucoma origins continues path toward potential cure
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... cellsas indicated by a molecular imaging techniquecould tell researchers ... headaches and psychosis in schizophrenic patients, occur and provide ... two studies published in the November issue of the ... positron emission tomography (PET)a noninvasive molecular imaging techniqueresearchers were ...
... When 100 m sprinters launches themselves from the starting blocks, ... few strides. Acceleration through the first few strides is the ... by an American football star, who sprints in his position ... his technique and training regime, Piazza decided to focus on ...
... have confirmed that the largest bat in Europe, ... the Late Pleistocene (between 120,000 and 10,000 years ago). ... at Abrc Roman (Barcelona) prove that this bat had ... than it does today, having declined due to the ...
Cached Biology News:Unlocking mysteries of the brain with PET 2Short heels make elite sprinters super speedy 2The largest bat in Europe inhabited northeastern Spain more than 10,000 years ago 2
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... commercial focus on China , today ... meeting with the U.S. Food and Drug Administration (FDA) ... 2015.  During this meeting the Company will seek guidance ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... - Injured soldiers in Iraq and Afghanistan are becoming ... a Madison-based company is developing counter-measures. , ,With a ... U.S. Army in hand, ConjuGon, Inc. ... antibiotic-resistant bacterial infections. , ,"We are pleased that the ...
... White Sox this year and as for the Cubs ... What we cannot "wait until next year" for is some real ... Chicago. , ,There should be as much buzz, if not more, ... teams that didn't even make the playoffs, but maybe the media ...
... - Patent law is esoteric territory, but a Madison court ... in the process it might be giving smaller drug companies ... , ,The most recent example occurred last month. After a ... jury in U.S. District Court for the Western District ...
Cached Biology Technology:Wait `till next year OK for baseball, not broadband 2Wait `till next year OK for baseball, not broadband 3Wait `till next year OK for baseball, not broadband 4Wait `till next year OK for baseball, not broadband 5With patents, Wisconsin court gaining reputation as a "rocket docket" 2With patents, Wisconsin court gaining reputation as a "rocket docket" 3With patents, Wisconsin court gaining reputation as a "rocket docket" 4
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Active GST Protein...
Marmoset plasma and serum - various quantities available...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Biology Products: